Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
NCT05630963
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Major Depressive Disorder
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mclean Hospital
- Last updated on ClinicalTrials.gov
- October 21, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- McLean Hospital · Belmont, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.